Mark Capone, a former chief executive of Myriad Genetics Inc, has joined the board of UK-based Owlstone Medical Ltd to help it advance its breath-based diagnostics for cancer and respiratory disease. Prior to Myriad, Mr Capone worked at Eli Lilly and Co for 17 years. Currently he is CEO of Precision Medicine Advisors LLC. In addition to being a non-executive director at Owlstone, Mr Capone holds non-executive board positions at Abcam Plc, Micoba Life Sciences Ltd and NephroSant Inc.
Owlstone Medical announced the appointment on 16 September 2021.
Copyright 2021 Evernow Publishing Ltd